CR20130572A - Formulaciones de liberación sostenida de paracetamol - Google Patents
Formulaciones de liberación sostenida de paracetamolInfo
- Publication number
- CR20130572A CR20130572A CR20130572A CR20130572A CR20130572A CR 20130572 A CR20130572 A CR 20130572A CR 20130572 A CR20130572 A CR 20130572A CR 20130572 A CR20130572 A CR 20130572A CR 20130572 A CR20130572 A CR 20130572A
- Authority
- CR
- Costa Rica
- Prior art keywords
- sustained release
- paracetamol
- release formulations
- release phase
- paracetamol sustained
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención presente está dirigida a una composiciónfarmacéutica de liberación sostenida de dos veces al día de paracetamol que tiene una fase de liberación inmediata de paracetamol y una 5 fase de liberación sostenida de paracetamol, dicha composición tiene propiedades farmacocinéticas únicas y ventajosas y una composición farmacéutica que comprende sólo una fase de liberación sostenida de paracetamol que tienepropiedades farmacocinéticas únicas y ventajosas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161483320P | 2011-05-06 | 2011-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20130572A true CR20130572A (es) | 2014-03-20 |
Family
ID=47139543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20130572A CR20130572A (es) | 2011-05-06 | 2013-11-06 | Formulaciones de liberación sostenida de paracetamol |
Country Status (19)
Country | Link |
---|---|
US (1) | US20140065213A1 (es) |
EP (1) | EP2704697B1 (es) |
CN (1) | CN103648486A (es) |
AP (1) | AP3878A (es) |
AU (1) | AU2012253834B2 (es) |
BR (1) | BR112013028668A2 (es) |
CA (1) | CA2835330A1 (es) |
CL (1) | CL2013003176A1 (es) |
CO (1) | CO6801767A2 (es) |
CR (1) | CR20130572A (es) |
DO (1) | DOP2013000258A (es) |
EA (1) | EA201391643A1 (es) |
GT (1) | GT201300270A (es) |
MX (1) | MX2013012918A (es) |
NI (1) | NI201300116A (es) |
SG (1) | SG194605A1 (es) |
TW (1) | TW201306881A (es) |
WO (1) | WO2012154563A1 (es) |
ZA (1) | ZA201308316B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
TW201507726A (zh) * | 2013-05-10 | 2015-03-01 | Glaxosmithkline Llc | 菸鹼菱形錠配製物 |
BE1021194B1 (nl) * | 2014-07-07 | 2015-07-14 | Nordic Specialty Pharma Bvba | Paracetamol tabletten |
PL3265126T3 (pl) | 2015-03-03 | 2021-12-06 | Saniona A/S | Preparaty połączenia tesofensyny i metoprololu |
BE1023116B1 (nl) * | 2015-07-24 | 2016-11-23 | Nordic Specialty Pharma Bvba | Paracetamol omvattend preparaat met vertraagde en aanhoudende afgifte |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4820522A (en) * | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
GB8724763D0 (en) * | 1987-10-22 | 1987-11-25 | Aps Research Ltd | Sustained-release formulations |
US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
KR100354702B1 (ko) * | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
US20030064108A1 (en) * | 1996-04-23 | 2003-04-03 | Stefan Lukas | Taste masked pharmaceutical compositions |
AUPN940796A0 (en) * | 1996-04-23 | 1996-05-16 | F.H. Faulding & Co. Limited | Taste masked pharmaceutical compositions |
EP1017370B1 (en) * | 1997-09-11 | 2003-10-29 | Nycomed Danmark ApS | MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs) |
IL141762A0 (en) * | 1998-10-01 | 2002-03-10 | Novartis Ag | New oral formulations |
GB0009522D0 (en) * | 2000-04-19 | 2000-06-07 | Smithkline Beecham Plc | Composition |
GB0114069D0 (en) * | 2001-06-08 | 2001-08-01 | Smithkline Beecham Plc | Composition |
CA2491355A1 (en) * | 2002-07-05 | 2004-01-15 | Temrel Limited | Controlled release compositions comprising coated pellets having non-uniform coating thicknesses |
MXPA06003454A (es) * | 2003-09-26 | 2006-08-31 | Johnson & Johnson | Formulaciones de liberacion controlada de analgesicos opioides y no opiodes. |
US20080031901A1 (en) * | 2004-09-24 | 2008-02-07 | Abbott Laboratories | Sustained release monoeximic formulations of opioid and nonopioid analgesics |
PL1781277T3 (pl) * | 2004-07-07 | 2012-07-31 | Aft Pharmaceuticals Ltd | Kompozycja łączona zawierająca ibuprofen i paracetamol |
MX2010008420A (es) * | 2008-02-01 | 2012-09-19 | Abbott Lab | Hidrocodona acetaminofen de liberacion extendida y metodos relacionados y sus usos. |
WO2009114648A1 (en) * | 2008-03-11 | 2009-09-17 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
US20100104638A1 (en) * | 2008-10-27 | 2010-04-29 | Wei-Guo Dai | Extended release oral acetaminophen/tramadol dosage form |
US8021420B2 (en) * | 2009-03-12 | 2011-09-20 | Medtronic Vascular, Inc. | Prosthetic valve delivery system |
EP2473195A4 (en) * | 2009-08-31 | 2013-01-16 | Depomed Inc | PHARMACEUTICAL MAGNETIC RELEASE COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF ACETAMINOPHES |
-
2012
- 2012-05-04 EA EA201391643A patent/EA201391643A1/ru unknown
- 2012-05-04 AP AP2013007224A patent/AP3878A/en active
- 2012-05-04 MX MX2013012918A patent/MX2013012918A/es not_active Application Discontinuation
- 2012-05-04 BR BR112013028668A patent/BR112013028668A2/pt active Search and Examination
- 2012-05-04 WO PCT/US2012/036528 patent/WO2012154563A1/en active Application Filing
- 2012-05-04 CA CA2835330A patent/CA2835330A1/en not_active Abandoned
- 2012-05-04 EP EP12782731.9A patent/EP2704697B1/en active Active
- 2012-05-04 AU AU2012253834A patent/AU2012253834B2/en active Active
- 2012-05-04 SG SG2013078928A patent/SG194605A1/en unknown
- 2012-05-04 TW TW101116070A patent/TW201306881A/zh unknown
- 2012-05-04 CN CN201280033402.0A patent/CN103648486A/zh active Pending
- 2012-05-04 US US14/115,896 patent/US20140065213A1/en not_active Abandoned
-
2013
- 2013-11-01 CO CO13259868A patent/CO6801767A2/es not_active Application Discontinuation
- 2013-11-04 NI NI201300116A patent/NI201300116A/es unknown
- 2013-11-05 GT GT201300270A patent/GT201300270A/es unknown
- 2013-11-06 DO DO2013000258A patent/DOP2013000258A/es unknown
- 2013-11-06 CR CR20130572A patent/CR20130572A/es unknown
- 2013-11-06 CL CL2013003176A patent/CL2013003176A1/es unknown
- 2013-11-06 ZA ZA2013/08316A patent/ZA201308316B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201308316B (en) | 2014-07-30 |
NI201300116A (es) | 2014-11-13 |
CN103648486A (zh) | 2014-03-19 |
WO2012154563A1 (en) | 2012-11-15 |
TW201306881A (zh) | 2013-02-16 |
DOP2013000258A (es) | 2014-07-15 |
NZ617198A (en) | 2016-01-29 |
MX2013012918A (es) | 2013-11-21 |
EP2704697B1 (en) | 2018-09-12 |
AP2013007224A0 (en) | 2013-11-30 |
AU2012253834A1 (en) | 2013-12-05 |
EP2704697A1 (en) | 2014-03-12 |
US20140065213A1 (en) | 2014-03-06 |
EP2704697A4 (en) | 2015-01-07 |
AP3878A (en) | 2016-10-31 |
CO6801767A2 (es) | 2013-11-29 |
CL2013003176A1 (es) | 2014-07-04 |
EA201391643A1 (ru) | 2014-07-30 |
GT201300270A (es) | 2014-12-16 |
CA2835330A1 (en) | 2012-11-15 |
AU2012253834B2 (en) | 2016-06-16 |
SG194605A1 (en) | 2013-12-30 |
BR112013028668A2 (pt) | 2017-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1125061T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει δροσπιρενονη για χρηση ως ενα αντισυλληπτικο | |
BR112014017021A2 (pt) | inibidores de irak e usos dos mesmos | |
EA201101620A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
BR112013007362A2 (pt) | composição farmacêutica | |
CL2013003145A1 (es) | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre. | |
MY163083A (en) | Solid forms of a pharmaceutically active substance | |
CY1121999T1 (el) | Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης | |
BR112015016930A2 (pt) | formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina | |
CR20120008A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
BR112015009228A2 (pt) | soluções estáveis anti-inflamatórias e midriáticas livres de conservantes para injeção | |
GT201200284A (es) | Composición farmacéutica | |
CY1119446T1 (el) | Φαρμακοτεχνικες μορφες δαρουναβιρης | |
BR112015006731A2 (pt) | combinações e usos das mesmas | |
CR20130572A (es) | Formulaciones de liberación sostenida de paracetamol | |
BR112015002824A2 (pt) | composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação. | |
BR112014025041B8 (pt) | Composição farmacêutica | |
EA201100286A1 (ru) | Композиция кветиапина | |
EA201291211A1 (ru) | Фармацевтические композиции, содержащие гидроморфон и налоксон | |
CO7131388A2 (es) | Métodos de quelatos de oligonucleótidos | |
EA201200616A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
BR112014005935A2 (pt) | derivados de anilina, sua preparação e sua aplicação terapêutica | |
EA201101118A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
ES2415029A8 (es) | Composición farmacéutica y uso de un anticuerpo para preparar un medicamento destinado a inhibir la producción o amplificar la eliminación de la proteína P24. | |
UY31128A1 (es) | Formulacion de nevirapina de liberacion prolongada | |
BR112015023878A2 (pt) | composto, composição farmacêutica, e, uso de um composto |